Correspondence 0001213900-23-030034 from Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc.
Date: April 17, 2023 · CIK: 0001860657 · Accession: 0001213900-23-030034
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-270514
Letter
24 School Street, 2nd Floor
Boston, MA 02108
April 17, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Joshua R. Gorsky
Re: Allarity Therapeutics, Inc.
Registration Statement on Form S-1 (File No. 333-270514)
Request for Acceleration
Requested Date: April 17, 2023
Requested Time: 5:00 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests that the effective date of its Registration Statement on Form S-1, as amended, (File No. 333-270514) be accelerated so that the same will become effective at 5:00 p.m., Eastern Time, on April 17, 2023, or as soon thereafter as is practicable.
If you have any questions regarding this request, please contact our counsel Daniel B. Eng of Lewis Brisbois Bisgaard & Smith LLP at (415) 262-8508.
Very Truly Yours,
Allarity Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
24 School Street, 2nd Floor
Boston, MA 02108
April 17, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Joshua R. Gorsky
Re:
Allarity Therapeutics, Inc.
Registration Statement on Form S-1 (File No. 333-270514)
Request for Acceleration
Requested Date: April 17, 2023
Requested Time: 5:00 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities
Act of 1933, as amended, the undersigned hereby respectfully requests that the effective date of its Registration Statement on Form S-1,
as amended, (File No. 333-270514) be accelerated so that the same will become effective at 5:00 p.m., Eastern Time, on April 17, 2023,
or as soon thereafter as is practicable.
If you have any questions regarding this request,
please contact our counsel Daniel B. Eng of Lewis Brisbois Bisgaard & Smith LLP at (415) 262-8508.
Very Truly Yours,
Allarity Therapeutics, Inc.
By:
/s/ Joan Brown
Name:
Joan Brown
Title:
Chief Financial Officer